Diabetes drug may shield hepatitis b patients from liver failure
NCT ID NCT06364930
First seen Mar 24, 2026 · Last updated Jun 19, 2026 · Updated 14 times
Summary
This 5-year study tests whether dapagliflozin, a diabetes drug, can prevent serious liver complications in people with chronic hepatitis B and diabetes who already have early liver scarring. 412 participants will receive either dapagliflozin or a placebo daily. The goal is to see if the drug reduces the risk of liver cancer, fluid buildup, bleeding, or other liver-related events.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Prince of Wales Hospital
RECRUITINGHong Kong, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dapagliflozin
What this could lead to
If it works, this could show that dapagliflozin reduces the risk of serious liver problems like liver cancer or fluid buildup in people with hepatitis B and diabetes.
What could go wrong
This is a Phase 4 trial, so dapagliflozin is already approved for diabetes, but its benefit for liver complications is unproven. The 5-year study may not show a clear effect, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.